296 related articles for article (PubMed ID: 31332498)
21. Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer.
Barakat A; Yacoub B; Homsi ME; Saad Aldine A; El Hajj A; Haidar MB
Sci Rep; 2020 Feb; 10(1):2705. PubMed ID: 32066750
[TBL] [Abstract][Full Text] [Related]
22. Impact of
Schmidt-Hegemann NS; Eze C; Li M; Rogowski P; Schaefer C; Stief C; Buchner A; Zamboglou C; Fendler WP; Ganswindt U; Cyran C; Bartenstein P; Belka C; Ilhan H
J Nucl Med; 2019 Jul; 60(7):963-970. PubMed ID: 30552203
[No Abstract] [Full Text] [Related]
23.
Hamed MAG; Basha MAA; Ahmed H; Obaya AA; Afifi AHM; Abdelbary EH
Acad Radiol; 2019 Apr; 26(4):450-460. PubMed ID: 29935970
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
Gasparro D; Scarlattei M; Manuguerra R; Guglielmo P; Migliari S; Sammartano A; Baldari G; Maestroni U; Silini EM; Ruffini L
Clin Nucl Med; 2021 Sep; 46(9):e458-e460. PubMed ID: 34374683
[TBL] [Abstract][Full Text] [Related]
25. Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT).
Tariq A; McGeorge S; Pearce A; Rhee H; Wood S; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Roberts MJ
Urol Oncol; 2022 Jun; 40(6):276.e1-276.e9. PubMed ID: 35466037
[TBL] [Abstract][Full Text] [Related]
26. Impact of
Ferraro DA; Garcia Schüler HI; Muehlematter UJ; Eberli D; Müller J; Müller A; Gablinger R; Kranzbühler H; Omlin A; Kaufmann PA; Hermanns T; Burger IA
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):652-664. PubMed ID: 31802175
[TBL] [Abstract][Full Text] [Related]
27. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
28.
Caroli P; Sandler I; Matteucci F; De Giorgi U; Uccelli L; Celli M; Foca F; Barone D; Romeo A; Sarnelli A; Paganelli G
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948
[TBL] [Abstract][Full Text] [Related]
29.
Lengana T; Lawal IO; Boshomane TG; Popoola GO; Mokoala KMG; Moshokoa E; Maes A; Mokgoro NP; Van de Wiele C; Vorster M; Sathekge MM
Clin Genitourin Cancer; 2018 Oct; 16(5):392-401. PubMed ID: 30120038
[TBL] [Abstract][Full Text] [Related]
30. Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.
Urso L; Castello A; Rocca GC; Lancia F; Panareo S; Cittanti C; Uccelli L; Florimonte L; Castellani M; Ippolito C; Frassoldati A; Bartolomei M
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1299-1311. PubMed ID: 35217902
[TBL] [Abstract][Full Text] [Related]
31. Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis.
Singhal T; Singh P; Parida GK; Agrawal K
Ann Nucl Med; 2024 Mar; 38(3):176-187. PubMed ID: 38340144
[TBL] [Abstract][Full Text] [Related]
32. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.
Pathmanathan S; Tariq A; Pearce A; Rhee H; Kyle S; Raveenthiran S; Wong D; McBean R; Marsh P; Goodman S; Dhiantravan N; Esler R; Dunglison N; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Goh JC; Gan CL; Roberts MJ
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):295-303. PubMed ID: 37592084
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of early imaging with
Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):100-105. PubMed ID: 30514659
[TBL] [Abstract][Full Text] [Related]
35. A prospective intra-individual comparison of [
Lawal IO; Mokoala KMG; Mahapane J; Kleyhans J; Meckel M; Vorster M; Ebenhan T; Rösch F; Sathekge MM
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):134-142. PubMed ID: 32424485
[TBL] [Abstract][Full Text] [Related]
36. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
McEwan L; McBean R; Yaxley J; Wong D
J Med Imaging Radiat Oncol; 2019 Jun; 63(3):318-323. PubMed ID: 30840361
[TBL] [Abstract][Full Text] [Related]
37. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
38.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
39.
Parghane RV; Basu S
J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
[TBL] [Abstract][Full Text] [Related]
40. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging of Selected Renal Tumours: Initial Experience in a Multicentre Cohort.
Tariq A; Pearce A; Rhee H; Kyle S; Raveenthiran S; Pelecanos A; Gan CL; Goh JC; Wong D; McBean R; Marsh P; Goodman S; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
Eur Urol Focus; 2024 Jan; ():. PubMed ID: 38195354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]